The bill seeks to amend South Dakota's controlled substances law by rescheduling crystalline polymorph psilocybin from Schedule I to Schedule IV. This change allows for the inclusion of psilocybin in FDA-approved drug products, reflecting a shift in its classification from a substance with a high potential for abuse and no accepted medical use to one with a lower potential for abuse and recognized medical applications. The proposed amendment specifically inserts legal language that identifies psilocybin as a controlled substance under Schedule IV, facilitating its use in medical treatments while maintaining regulatory oversight.

In addition to rescheduling psilocybin, the bill outlines various compounds derived from phenylethan-2-amine and 2-(1H-indol-3-yl)ethanamine, detailing the modifications that would classify them as controlled substances unless exempt. This comprehensive approach includes listing numerous trade names for these compounds, aiming to enhance public safety by regulating emerging psychoactive substances that may pose health risks. Overall, the legislation reflects a growing recognition of the therapeutic potential of psilocybin, particularly in mental health treatment, while ensuring appropriate controls are in place.

Statutes affected:
Introduced, 01/20/2026: 34-20B-14, 34-20B-25
Enrolled, 03/03/2026: 34-20B-14, 34-20B-25